메뉴 건너뛰기
Nephrology Dialysis Transplantation
Volumn 22, Issue 2, 2007, Pages 671-672
Unexpected rate of severe leucopenia with the association of mycophenolate mofetil and valganciclovir in kidney transplant recipients [12]
Author keywords

[No Author keywords available]
Indexed keywords

ANTIBIOTIC AGENT; COTRIMOXAZOLE; CYCLOSPORIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; VALGANCICLOVIR;
EID: 33846671510     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl539     Document Type: Letter
Times cited : (27)
References (6)
  • 1
    • 1942469969 scopus 로고    scopus 로고
    • Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients
    • Paya C, Humar A, Dominguez E et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611-620
    • (2004) Am J Transplant , vol.4 , pp. 611-620
    • Paya, C.1    Humar, A.2    Dominguez, E.3
  • 2
    • 21344457268 scopus 로고    scopus 로고
    • Treatment of cytomegalovirus infection or disease in solid organ transplant recipients with valganciclovir
    • Fellay J, Venetz JP, Pascual M, Aubert JD, Seydoux C, Meylan PRA. Treatment of cytomegalovirus infection or disease in solid organ transplant recipients with valganciclovir. Am J Transplant 2005; 5: 1781-1782
    • (2005) Am J Transplant , vol.5 , pp. 1781-1782
    • Fellay, J.1    Venetz, J.P.2    Pascual, M.3    Aubert, J.D.4    Seydoux, C.5    Meylan, P.R.A.6
  • 3
    • 3943066445 scopus 로고    scopus 로고
    • Treatment of cytomegalovirus disease with valganciclovir in renal transplant recipients: A single center experience
    • Babel N, Gabdrakhmanova L, Juerguensen JS et al. Treatment of cytomegalovirus disease with valganciclovir in renal transplant recipients: A single center experience. Transplantation 2004; 78: 283-285
    • (2004) Transplantation , vol.78 , pp. 283-285
    • Babel, N.1    Gabdrakhmanova, L.2    Juerguensen, J.S.3
  • 4
    • 19944369050 scopus 로고    scopus 로고
    • Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease
    • Taber DJ, Ashcraft E, Baillie GM et al. Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease. Transp Infect Dis 2004; 6: 101-109
    • (2004) Transp Infect Dis , vol.6 , pp. 101-109
    • Taber, D.J.1    Ashcraft, E.2    Baillie, G.M.3
  • 5
    • 0042536429 scopus 로고    scopus 로고
    • Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation
    • Knoll GA, MacDonald I, Khan A, Van Walraven. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003; 14: 2414-2416
    • (2003) J Am Soc Nephrol , vol.14 , pp. 2414-2416
    • Knoll, G.A.1    MacDonald, I.2    Khan, A.3    Van Walraven4
  • 6
    • 3242793473 scopus 로고    scopus 로고
    • Evaluation of pharmacokinetic interactions after oral administration of mycophenolate mofetil and valaciclovir or aciclovir to healthy subjects
    • Gimenez F, Foeillet E, Bourdon O et al. Evaluation of pharmacokinetic interactions after oral administration of mycophenolate mofetil and valaciclovir or aciclovir to healthy subjects. Clin Pharmacokinet 2004; 43: 685-692
    • (2004) Clin Pharmacokinet , vol.43 , pp. 685-692
    • Gimenez, F.1    Foeillet, E.2    Bourdon, O.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.